Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and raises the price target from $45 to $49.
June 28, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Silence Therapeutics and raises the price target from $45 to $49.
The Overweight rating and increased price target from a reputable analyst at Morgan Stanley are likely to boost investor confidence and positively impact the stock price of Silence Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100